September 2019 Price Concessions – 1st update


September 2019 Price Concessions – 1st update

September 20, 2019

Department of Health and Social Care (DHSC) has today granted the following initial list of price concessions:

Drug Pack Size Price concession
Betahistine 8mg tablets 84 £1.65
Betahistine 16mg tablets 84 £2.99
Co-careldopa 12.5mg/50mg tablets 90 £10.73
Cyclizine 50mg/1ml solution for injection ampoules 5 £14.00
Escitalopram 10mg tablets 28 £3.19
Ibandronic acid 150mg tablets 1 £6.81
Irbesartan 300mg tablets 28 £6.93
Levetiracetam 1g tablets 60 £9.99
Metoprolol 100mg tablets 28 £3.12
Mirtazapine 30mg tablets 28 £1.74
Mometasone 50micrograms/dose nasal spray 140 £4.30
Pantoprazole 20mg gastro-resistant tablets 28 £1.95
Pantoprazole 40mg gastro-resistant tablets 28 £2.70
Prednisolone 5mg tablets 28 £1.47
Quinine sulfate 300mg tablets 28 £6.91
Risedronate sodium 35mg tablets 4 £11.15
Tamoxifen 20mg tablets 30 £3.36
Valsartan 80mg capsules 28 £9.45

No additional endorsements are required for price concessions. A price concession only applies for the month in which it is granted.

PSNC is still working with the DHSC to agree further concessionary prices on other drugs reported to be unavailable at the stated September 2019 Drug Tariff price. Contractors will be alerted to further updates to the price concession list through our website and via our e-news email.  If you wish to subscribe to our email list, you can receive an email as soon as any announcements are made. Please note that PSNC cannot provide details of any generic products awaiting price concession approval from DHSC.

If you have problems obtaining a Part VIII product or problems obtaining the product at the stated Drug Tariff price, please report the issue to PSNC using the online feedback form on the PSNC Website.
Please include full details of the supplier and price paid for any products sourced above the Drug Tariff price. PSNC will investigate the extent of the problem and if appropriate discuss the issue with DHSC.

Posted in:

More Latest News >